News

H2020-EIC-SMEInst-2018-2020 – Update Brexit

Published on | 5 years ago

Programmes SME Instrument EIC Pilot

As of 1 February 2020, the United Kingdom formally leaves the European Union. In accordance with the Withdrawal Agreementapplicants located in the UK are:

a. Eligible for grants (including the EIC Accelerator) until the end of the transition period on 31 December 2020. They are entitled to receive EU grant funding to carry out their projects until the projects’ lifetime is completed, including projects finishing after the end of the transition period.

b. Not eligible for EIC Accelerator Pilot equity support as of 1 February 2020.

The section on eligible countries under the heading Topic conditions and documents has also been updated accordingly.

Source: Funding and Tender Portal

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Latest News

1745 articles available search in articles 

Testimonial

image of BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment

BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment

The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.